SignalRX Pharmaceuticals
Cumming, US · Delaware corporation
Biotech
Founders & leadership
GM
Guillermo MoralesDirector
JW
Joel WernickDirector
MW
Matthew WilliamsDirector and Chief Executive Officer
Reported raises · per SEC filings
Form D private placements▶$250KraisedMay 2023 · 2 investors · PharmaceuticalsRule 506(b)
▶$250KraisedMay 2023 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Guillermo MoralesDirector
- Joel WernickDirector
- Matthew WilliamsExecutive Officer, Director
- Offering amount
- $485K
- Amount sold
- $250K
- Minimum investment
- $25K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $209K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.